14.40USD-0.86%Mkt Cap: 877.02M USDP/E: —Last update: 2026-05-26
Janux Therapeutics, Inc., a clinical stage biopharmaceutical company, develops immunotherapies based on Tumor Activated T Cell Engager (TRACTr), Tumor Activated Immunomodulator (TRACIr), and Adaptive Immune Response Modu…
Industry Peers
Biotechnology110.61BUSDP/E 25.8
105.81BDKKP/E 20.4
66.47BUSDP/E 15.5
46.56BEURP/E 30.5
43.89BEURP/E 36.5
39.41BUSDP/E 74.0
32.84BUSD—
32.05BSEKP/E 47.4
Indicators:|
Key Statistics
Company
Market Cap877.02M USD
Enterprise Value-56.03M USD
Revenue (TTM)13.73M USD
Gross Profit-113.92M USD
Net Income (TTM)-113.63M USD
Revenue/Share0.2210 USD
Last Price14.40 USD
Fiscal Year EndDec 2025
MR QuarterMar 2026
Employees108
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)-5.20
PEG—
EV/EBITDA0.36
EV/Revenue-4.08
P/S63.99
P/B0.93
EPS (TTM)-1.84
EPS (Forward)-2.77
52W Range
12.1210% of range35.34
52W High35.34 USD
52W Low12.12 USD
Profitability
Gross Margin0.00%
Oper. Margin-916.50%
EBITDA Margin0.00%
Profit Margin-1136.25%
ROE-11.88%
ROA-11.34%
Growth
Revenue Growth—
Earnings Growth—
Cash Flow & Leverage
Operating CF-82.23M USD
CapEx (TTM)1.04M USD
FCF Margin-393.29%
FCF Yield-6.16%
Net Debt-934.81M USD
Net Debt/EBITDA6.03
Balance Sheet
Debt/Equity0.02
Current Ratio17.01
Quick Ratio16.95
Book Value/Sh15.47 USD
Cash/Share15.68 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 USD
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating1.5 (Buy)
Target (Mean)40.56 USD
Target Range14.00 USD – 80.00 USD
# Analysts16
Ownership
Shares Out.60.98M
Float39.20M
Insiders6.73%
Institutions102.56%
Short Interest
Short Ratio7.9d
Short % Float16.67%
Short % Out.13.01%
Shares Short7.93M
Short (prev mo.)7.74M
Technical
SMA 5014.43 (-0.3%)
SMA 20018.99 (-24.2%)
Beta2.57
S&P 52W Chg28.31%
Avg Vol (30d)981.23K
Avg Vol (10d)1.10M
Technical Indicators
RSI (14)—
MACD—
MACD Signal—
MACD Hist.—
BB Upper—
BB Middle—
BB Lower—
BB Width—
ATR (14)—
Vol Ratio (20d)—